Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial
14 sept. 2023 14h59 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, is pleased...
Optimi Health Granted Amendment to Dealer's Licence by Health Canada to Supply Special Access Program
07 sept. 2023 07h30 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, proudly...
Optimi Health Announces Second Tranche of CAD $1,000,000 Secured for Debt Financing
05 sept. 2023 07h30 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian drug research and formulation...
Optimi Health Announces CAD $3,000,000 Senior Debt Financing
10 août 2023 07h30 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian drug research and formulation company licensed by Health Canada...
Optimi Health To Supply MDMA For Therapist Experiential Training Program at Numinus, Supported by MAPS
15 juin 2023 09h40 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, June 15, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator...
Optimi Health Completes Harvest Of Psilocybe Cubensis For Delivery To The Australian Medical Market
17 mai 2023 08h15 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, May 17, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator...
Optimi Health Granted Natural Health Product Site Licence By Health Canada
10 mai 2023 08h45 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, May 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator...
Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement for Clinical Research and Development
04 mai 2023 09h00 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, May 04, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), today announced that it has entered into a...
Optimi Health Enters Australian Medical MDMA And Psilocybin Market With Mind Medicine Australia Distribution Agreement
01 mars 2023 07h30 HE
|
Optimi Health Corp.
Highlights: Signed Purchase Orders with Mind Medicine Australia to ensure that patients with treatment resistant post-traumatic stress disorder (PTSD) have access to medical grade GMP MDMA (using...
Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists
07 févr. 2023 10h31 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end Canadian-based drug manufacturer...